Nikolai V. Naoumov

Honorary Professor, Hepatology at University College London

Nikolai V. Naoumov

Nikolai V. Naoumov

Honorary Professor, Hepatology at University College London

Biography

Nikolai V. Naoumov, M.D., Ph.D.
Scientific Advisory Board

Nikolai Naoumov works at Novartis Global Drug Development, based in Basel, Switzerland. His focus is on developing new therapies for patients with liver diseases such as NASH, autoimmune diseases, liver fibrosis and complications of cirrhosis, closely interacting with clinical and research teams. In addition to his work at Novartis Global, Nikolai is also Honorary Professor of Hepatology, University College London and Honorary Scientific Advisor to the Foundation for Liver Research in the UK. Before joining Novartis in 2007, Nikolai was a tenured Professor of Hepatology at University College London and Consultant Hepatologist at University College London Hospitals. His work effectively combined hands-on laboratory research in liver immunology and molecular biology with extensive clinical insights and elucidated the relationship between replication, mutations, protein expression of hepatitis viruses and virus-specific immunity in the pathogenesis of liver damage caused by hepatitis B virus (HBV), hepatitis C virus (HCV), cytomegalovirus (CMV), hepatitis Delta virus (HDV) and TT-virus. Nikolai has been involved in the development and evaluation of many of the new treatments for patients with liver diseases, initially at the Institute of Liver Studies, King’s College Hospital, London and subsequently at the Institute of Hepatology, University College London. Nikolai has more than 200 publications in the fields of liver immunology, treatment of viral hepatitis and liver transplantation. He is Fellow of both the Royal College of Physicians (London) and the Royal College of Pathologists in the UK, member of the Association of Physicians of Great Britain and Northern Ireland, and was amongst the first to be elected as a Fellow of the American Association for the Study of Liver Diseases (AASLD).

Overview
RelSci Relationships

206

Number of Boards

2

Relationships
RelSci Relationships are individuals Nikolai V. Naoumov likely has professional access to. A relationship does not necessarily indicate a personal connection.

Scientific Advisor at Abliva AB

Relationship likelihood: Strong

President, Chief Executive Officer & Director at Hepion Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Operating Officer, Chief Scientific Officer at Ocera Subsidiary, Inc.

Relationship likelihood: Strong

Founder at CTI Clinical Trial & Consulting Services, Inc.

Relationship likelihood: Strong

Medical Director, Research Center at University of Southern California

Relationship likelihood: Strong

Chief Development Officer at The Medicines Co.

Relationship likelihood: Strong

Former Managing Director, President of Canaccord Adams Inc. & Head of Investment Banking (US) at Canaccord Genuity Group, Inc.

Relationship likelihood: Average

Chief Investment Officer & Director at H-Source, Inc.

Relationship likelihood: Average

Editor-in-Chief of Future Internet Journal at University College London

Relationship likelihood: Average

Vice Provost, Education & Student Affairs at University College London

Relationship likelihood: Average

Paths to Nikolai V. Naoumov
Potential Connections via
Relationship Science
You
Nikolai V. Naoumov
Honorary Professor, Hepatology at University College London
Career History
Honorary Professor, Hepatology
Current

University College London (UCL) is a public research university in London, England, and the oldest and largest constituent college of the federal University of London. Founded in 1826 as London University, UCL was the first university institution established in London and the first in England to be entirely secular, to admit students regardless of their religion, and to admit women on equal terms with men. The philosopher Jeremy Bentham is commonly regarded as the spiritual father of UCL, as his radical ideas on education and society were the inspiration to its founders, although his direct involvement in its foundation was limited. UCL became one of the two founding colleges of the University of London in 1836. It has grown through mergers, including with the Institute of Neurology (in 1997), the Royal Free Hospital Medical School (in 1998), the Eastman Dental Institute (in 1999), the School of Slavonic and East European Studies (in 1999) and the School of Pharmacy (in 2012). UCL's main campus is located in the Bloomsbury area of central London, with a number of institutes and teaching hospitals located elsewhere in central London, and satellite campuses in Adelaide, Australia and Doha, Qatar. UCL is organised into 10 constituent faculties, within which there are over 100 departments, institutes and research centres. UCL has around 26,700 students and 11,025 staff and had a total income of £937 million in 2012/13, of which £335 million was from research grants and contracts. UCL has around 4,000 academic and research staff and 650 full professors, the highest number of any British university. UCL is responsible for several museums and collections in a wide range of fields across the arts and sciences, including the Petrie Museum of Egyptian Archaeology, a leading collection of Egyptian and Sudanese archaeology.

Boards & Committees
Member, Scientific Advisory Board
2016 - Current

Ciclofilin Pharmaceuticals, Inc. develops cyclophilin inhibitors for infectious, inflammatory and degenerative diseases. It offers Antiviral Drug Development, Liver Disease, Viral Co-Infection, Cyclophilin Inhibition, Macrocycle chemistry and Protein Folding. The company was founded in 2014 by Robert T. Foster and is headquartered in San Diego, PA.

Member, Scientific Advisory Board
Prior - 2019

Hepion Pharmaceuticals, Inc. engages in the development and commercialization of pleiotropic drug therapy for the treatment of chronic liver disease. It focuses on the development of its product candidate CRV431, a cyclophilin inhibitor that targets biochemical pathways involved in the progression of liver disease. The company was founded on May 15, 2013 and is headquartered in Edison, NJ.

Other Affiliations
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Nikolai V. Naoumov. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Nikolai V. Naoumov's profile does not indicate a business or promotional relationship of any kind between RelSci and Nikolai V. Naoumov.